Business Wire

Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis

- Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment - - These data, the longest-available outcomes data with ...
Law

The Staying Power of Continuation Fund Transactions and 'Traditional' M&A Considerations Background

Continuation funds emerged after 2008 to help fund managers transfer assets and raise new capital. They’ve grown as traditional exit options like M&A and IPOs became harder, especially during economic ...
Business Wire

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the ...
GameSpot

Continuity 2: The Continuation

Got an iPhone or iPad and an itch to play games? We help you sort though the best releases on the App Store in this week's top picks.